Latest advances in cannabinoid receptor antagonists and inverse agonists

Bibliography

• LAMBERT DM, FOWLER CJ: The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem. (2005) 48:5059-5087.
   PubMed Web of Science ®Google Scholar
• HOWLETT AC, BARTH F, BONNER TI et al.: International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. (2002) 54:161-202.
   PubMed Web of Science ®Google Scholar
• WILSON RI, NICOLL RA: Endocannabinoid signaling in the brain. Science (2002) 296:678-682.
   PubMed Web of Science ®Google Scholar
• MACKIE K: Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. (2006) 46:101-122.
   PubMed Web of Science ®Google Scholar
• DESPRES JP, GOLAY A, SJOESTROEM L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl. J. Med. (2005) 353:2121-2134.
   PubMed Web of Science ®Google Scholar
• VAN GAAL LF, RISSANEN AM, SCHEEN AJ, ZIEGLER O, ROSSNER S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365:1389-1397.
   PubMed Web of Science ®Google Scholar
• PI-SUNYER FX, ARONNE LJ, HESHMATI HM, DEVIN J, ROSENSTOCK J; RIO-NORTH AMERICAN STUDY GROUP: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-north america: a randomized controlled trial. J. Am. Med. Assoc. (2006) 295:761-775.
   PubMed Web of Science ®Google Scholar
• GELFAND EV, CANNON CP: Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J. Am. Coll. Cardiol. (2006) 47:1919-1926.
   PubMed Web of Science ®Google Scholar
• CLELAND JG, GHOSH J, FREEMANTLE N et al.: Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Failure (2004) 6:501-508.
   PubMed Web of Science ®Google Scholar
• TEIXEIRA-CLERC F, JULIEN B, GRENARD P et al.: CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. (2006) 12:671-676.
   PubMed Web of Science ®Google Scholar
• RINALDI-CARMONA M, BARTH F, HEAULME M et al.: Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. (1995) 56:1941-1947.
   PubMed Web of Science ®Google Scholar
• LANGE JH, KRUSE CG: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov. Today (2005) 10:693-702.
   PubMed Web of Science ®Google Scholar
• BARTH F, RINALDI-CARMONA M: The development of cannabinoid antagonists. Cur. Med. Chem. (1999) 6:745-755.
   PubMed Web of Science ®Google Scholar
• GOYA P, JAGEROVIC N: Recent advances in cannabinoid receptor agonists and antagonists. Expert Opin. Ther. Patents (2000) 10:1529-1538.
   Web of Science ®Google Scholar
• ADAM J, COWLEY P: Recent advances in the cannabinoids. Expert Opin.Ther. Patents (2002) 12:1475-1489.
   Web of Science ®Google Scholar
• LANGE JH, KRUSE CG: Recent advances in CB1 cannabinoid receptor antagonists. Curr. Opin. Drug Disc. Develop. (2004) 7:498-506.
   PubMed Web of Science ®Google Scholar
• HERTZOG DL: Recent advances in the cannabinoids. Expert Opin. Ther. Patents (2004) 14:1435-1452.
   Web of Science ®Google Scholar
• MUCCIOLI GG, LAMBERT DM: Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Cur. Med. Chem. (2005) 12:1361-1394.
   PubMed Web of Science ®Google Scholar
• LANGE JH, VAN STUIVENBERG HH, COOLEN HK et al.: Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists. J. Med. Chem. (2005) 48:1823-1838.
   PubMed Web of Science ®Google Scholar
• PLUMMER CW, FINKE PE, MILLS SG et al.: Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists. Bioorg. Med. Chem. Letters (2005) 15:1441-1446.
   PubMed Web of Science ®Google Scholar
• LANGE JH, COOLEN HK, VAN STUIVENBERG HH et al.: Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. J. Med. Chem. (2004) 47:627-643.
   PubMed Web of Science ®Google Scholar
• LANGE JH, VAN STUIVENBERG HH, VEERMAN W et al.: Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorg. Med. Chem. Letters (2005) 15:4794-4798.
   PubMed Web of Science ®Google Scholar
• DYCK B, GOODFELLOW VS, PHILLIPS T et al.: Potent imidazole and triazole CB1 receptor antagonists related to SR141716. Bioorg. Med. Chem. Letters (2004) 14:1151-1154.
   PubMed Web of Science ®Google Scholar
• JAGEROVIC N, HERNANDEZ-FOLGADO L, ALKORTA I et al.: Structural–activity relationship study on C-4 carbon atom of the CB1 antagonist SR141716: synthesis and pharmacological evaluation of 1,2,4-triazole-3-carboxamides. Eur. J. Med. Chem. (2006) 41:114-120.
   PubMed Web of Science ®Google Scholar
• MEURER LC, FINKE PE, MILLS SG et al.: Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists. Bioorg. Med. Chem. Letters (2005) 15:645-651.
   PubMed Web of Science ®Google Scholar
• STOIT AR, LANGE JH, DEN HARTOG AP et al.: Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. Chem. Pharm. Bul. (2002) 50:1109-1113.
   PubMed Web of Science ®Google Scholar
• MURINEDDU G, RUIU S, MUSSINU JM et al.: Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]- indazole-based ligands for cannabinoid receptors. Bioorg. Med. Chem. (2005) 13:3309-3320.
   PubMed Web of Science ®Google Scholar
• MURINEDDU G, RUIU S, LORIGA G et al.: Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2´,4´-dichloro phenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide. J. Med. Chem. (2005) 48:7351-7362.
   PubMed Web of Science ®Google Scholar
• CARPINO PA, GRIFFITH DA, SAKYA S et al.: New bicyclic cannabinoid receptor-1 (CB1-R) antagonists. Bioorg. Med. Chem. Letters (2006) 16:731-736.
   PubMed Web of Science ®Google Scholar
• FU J, GAETANI S, OVEISI F et al.: Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature (2003) 425:90-93.
   PubMed Web of Science ®Google Scholar
• GUZMAN M, LO VERME J, FU F, OVEISI F, BLAZQUEZ C, PIOMELLI D: Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α). J. Biol. Chem. (2004) 279:27849-27854.
   PubMed Web of Science ®Google Scholar
• SEGAL-LIEBERMAN G, BRADLEY RL, KOKKOTOU E et al.: Melanin-concentrating hormone is a critical mediator of the leptin-deficient phenotype. Proc. Natl. Acad. Sci. USA (2003) 100:10085-10090.
   PubMed Web of Science ®Google Scholar
• KIRKHAM TC, WILLIAMS CM: Synergistic effects of opioid and cannabinoid antagonists on food intake. (Berlin, Germany) Psychopharmacology (2001) 153:267-270.
   PubMed Web of Science ®Google Scholar
• VAN SICKLE MD, DUNCAN M, KINGSLEY PJ et al.: Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 310:329-332.
   PubMed Web of Science ®Google Scholar
• IDRIS AI, VAN'T HOF RJ, GREIG IR et al.: Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med. (2005) 11:774-779
   PubMed Web of Science ®Google Scholar
• OFEK O, KARSAK M, LECLERC N et al.: Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. USA (2006) 103:696-701.
   PubMed Web of Science ®Google Scholar
• IWAMURA H, SUZUKI H, UEDA Y, KAYA T, INABA T: In Vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J. Pharmacol. Exp. Ther. (2001) 296:420-425.
   PubMed Web of Science ®Google Scholar
• UEDA Y, MIYAGAWA N, MATSUI T, KAYA T, IWAMURA H: Involvement of cannabinoid CB2 receptor-mediated response and efficacy of cannabinoid CB2 receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur. J. Pharmacol. (2005) 520:164-171.
   PubMed Web of Science ®Google Scholar
• RAITIO KH, SAVINAINEN JR, VEPSALAINEN J et al.: Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists. J. Med. Chem. (2006) 49:2022-2027
   PubMed Web of Science ®Google Scholar
• LAVEY BJ, KOZLOWSKI JA, HIPKIN RW et al.: Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies. Bioorg. Med. Chem. Letters (2005) 15:783-786.
   PubMed Web of Science ®Google Scholar
• SHANKAR BB, LAVEY BJ, ZHOU G et al.: Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies. Bioorg. Med. Chem. Letters (2005) 15:4417-4420.
   PubMed Web of Science ®Google Scholar
• GONSIOREK W, HESK D, KINSLEY D et al.: Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [35S]SCH225336. J. Biol. Chem. (2006) ahead of print June 206 DOI 10.1074/jbc.M602364200.
   Google Scholar
• LUNN CA, FINE JS, ROJAS-TRIANA A et al.: A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J. Pharmacol. Exp. Ther. (2006) 316:780-788.
   PubMed Web of Science ®Google Scholar
• THOMAS A, STEVENSON LA, WEASE KN et al.: Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Brit. J. Pharmacol. (2005) 146:917-926.
   PubMed Web of Science ®Google Scholar
• RINALDI-CARMONA M, BARTH F, HEAULME M et al.: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350:240-244.
   PubMed Web of Science ®Google Scholar
• COTA D, MARSICANO G, TSCHOP M et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. (2003) 112:423-431.
   PubMed Web of Science ®Google Scholar
• RAVINET TRILLOU C, DELGORGE C, MENET C, ARNONE M, SOUBRIE P: CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. (2004) 28:640-648.
   Web of Science ®Google Scholar
• PAGOTTO U, CERVINO C, VICENNATI V, MARSICANO G, LUTZ B, PASQUALI R: How many sites of action for endocannabinoids to control energy metabolism? Int. J. Obes. (2006) 30:S39-S43.
   Google Scholar
• BENSAID M, GARY-BOBO M, ESCLANGON A et al.: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. (2003) 63:908-914.
   PubMed Web of Science ®Google Scholar
• POIRIER B, BIDOUARD JP, CADROUVELE C et al.: The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes. Metab. (2005) 7:65-72.
   PubMed Web of Science ®Google Scholar
• PERTWEE RG: Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci. (2005) 76:1307-1324.
   PubMed Web of Science ®Google Scholar
• GARDNER A, MALLET PE: Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. Eur. J. Pharmacol. (2006) 530:103-106.
   PubMed Web of Science ®Google Scholar
• RINALDI-CARMONA M, BARTH F, MILLAN J et al.: SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. (1998) 284:644-650.
   PubMed Web of Science ®Google Scholar